Aeglea Biotherapeutics’ (NASDAQ:AGLE) lock-up period is set to expire on Tuesday, October 4th. Aeglea Biotherapeutics had issued 5,000,000 shares in its initial public offering on April 7th. The total size of the offering was $50,000,000 based on an initial share price of $10.00. After the end of Aeglea Biotherapeutics’ lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
Separately, Zacks Investment Research raised shares of Aeglea Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, September 13th.
Shares of Aeglea Biotherapeutics (NASDAQ:AGLE) traded down 3.61% during trading on Friday, reaching $6.41. 12,245 shares of the company’s stock were exchanged. Aeglea Biotherapeutics has a 52-week low of $3.89 and a 52-week high of $12.75. The company has a 50 day moving average price of $6.38 and a 200-day moving average price of $6.58. The company’s market capitalization is $85.96 million.
Aeglea Biotherapeutics (NASDAQ:AGLE) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.03. On average, equities analysts forecast that Aeglea Biotherapeutics will post ($4.77) earnings per share for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Ghost Tree Capital LLC bought a new position in Aeglea Biotherapeutics during the second quarter valued at about $243,000. Perceptive Advisors LLC bought a new position in Aeglea Biotherapeutics during the second quarter valued at about $515,000. Finally, VHCP Management II LLC bought a new position in Aeglea Biotherapeutics during the second quarter valued at about $1,527,000. Institutional investors own 40.71% of the company’s stock.
Aeglea Biotherapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.
Receive News & Ratings for Aeglea Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.